Document is current
Any future updates will be listed below
-
Authors
Youhanna, John
Puig-Barberà, Joan
Miller, Matthew S.
Molrine, Deborah
Hadi, Monica
Bapat, Shweta
Iheanacho, Ike
Dodman, Sophie
Fikre, Tsion
Swinburn, Paul
,
De Haan, Cornelis A. M.
Fox, Annette
Marth, Jamey
Monto, Arnold S.
de Lejarazu, Raúl Ortiz
Plotkin, Stanley
Webby, Richard
- License Information
-
More Information
Article History
Received: 1 August 2024
Accepted: 26 November 2024
First Online: 11 January 2025
Declarations
:
: Institutional Review Board approval was not necessary according to Title 45 of the Code of Federal Regulations (CFR) Part 46, of the Health and Human Services (HHS) in the US. All study participants provided written informed consent.
: Not applicable.
: Potential conflicts of interest are as follows: John Youhanna and Deborah Molrine are employees of Seqirus which funded this study. Monica Hadi, Shweta Bapat, Ike Iheanacho, Sophie Dodman, Tsion Fikre, and Paul Swinburn are employees of Evidera, which received financial support from Seqirus for work on this study. Juan Puig-Barbera has received honoraria for consultancy work from Novavax, Seqirus/CSL, HIPRA, and Pfizer. Additionally, he received payment for his participation in the current Delphi panel. Matthew Miller has received honoraria for consultancy work from Seqirus, Sanofi, Evidera, and Grifols, and research funding from Pfizer and Providence Therapeutics. Matthew Miller is a co-founder of Aeroimmune Inc. Stanley Plotkin has received consulting remuneration from Merck, Moderna, Novavax, BNT, Ntx, Valneva, Vaxart, Sanofi, and GSK.
